

Supplementary Materials




Figure S1: Correlation between antibiotics resistance and *bla_{OXA-23}* location analyzed by Student's t test. Panels (A) to (M) showed the comparison of the logarithm of MICs of 13 antibiotics to the base of 2 between SI and CO isolates, respectively. If the data possessed unequal standard deviations (SDs), Welch's t tests were executed to correct the variances. The p-value was marked on the figures respectively. $P < 0.05$ specified a significant difference. The dotted lines displayed the logarithm of sensitive breakpoints to the base of 2.

IMP, imipenem; MEM, meropenem; CAZ, ceftazidime; FEP, cefepime; TZP, piperacillin/tazobactam; COL, colistin; DOX, doxycycline; MNO, minocycline; TGC, tigecycline; AMK, amikacin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, trimethoprim/sulfamethoxazole.



Figure S2: Gene presence and absence variants of CO and SI isolates. The red marked isolates represent CO isolates. The blue color shades indicated presence of the genes.




Figure S3: Blast analysis and visualization of *bla*_{OXA-23}-carrying plasmids. The blue color shades revealed the coverage and identity of sequence.

Table S1: Phenotypic and genotypic characteristics of SI *A. baumannii* isolates.

Isolate	Year of isolation	Characteristic						MIC (µg/mL)												
		Location	Origin /Source	ST s-Pa sur	ST s-Ox for d	Location of bla _{OXA-23}	Copy number of bla	Imipenem	Meropenem	Ceftazidime	Cefepime	TZP	Colistin	Doxycycline	Minocycline	Tigecycline	Amikacin	Ciprofloxacin	Levofloxacin	SXT
2016 BJAB 2	2016	China: Beijing	blood	2	208	plasmid	1	64	64	64	64	>256	1	64	8	2	>256	>32	32	32
2018 BJAB 3	2018	China: Beijing	blood	2	1968	chromosome	2	64	64	>128	128	>256	1	32	8	2	>256	>64	32	32
2013 GDA B1	2013	China: Guangzhou, Guangdong	blood	2	195	chromosome	1	64	64	>128	256	>256	1	32	8	1	>256	>32	32	64
2013 LNA B1	2013	China: Shenyang, Liaoning	sputum	2	208	chromosome	1	16	8	64	32	256	0.5	32	8	1	>256	>32	32	32

2013 GDA B2	201 3	China: Guangzhou, Guangdong	sputu m	2	19 5	chro moso me	2	64	64	>128	256	>256	0.5	32	8	2	>256	>32	64	128
2013 LNA B2	201 3	China: Shenyang, Liaoning	sputu m	2	20 8	chro moso me	1	32	16	64	32	>256	0.5	32	8	0.5	>256	>32	16	64
2014 BJAB 2	201 4	China: Beijing	urine	2	19 5	chro moso me	2	32	32	>128	256	>256	1	32	8	2	>256	>64	32	128
2014 SXA B1	201 4	China: Xi'an, Shanxi	blood	2	19 5	chro moso me	1	>32	64	>128	256	>256	1	32	4	0.5	>256	64	8	32
2015 BJAB 1	201 6	China: Beijing	blood	2	20 8	plas mid	1	>32	64	128	128	>256	1	32	8	1	>102 4	64	16	64
2011 GDA B1	201 1	China: Guangzhou, Guangdong	sputu m	2	45 7	chro moso me	1	16	16	>128	128	256	1	32	4	2	>256	>32	32	0.25
2013 BJAB 1	201 3	China: Beijing	sputu m	2	19 5	chro moso me	2	64	64	>128	256	>256	0.5	32	4	2	>256	>32	16	64
2013 BJAB 2	201 3	China: Beijing	blood	57 0	49 3	chro moso me	1	32	16	64	64	>256	1	0.5	0.5	0.5	>256	>32	>64	2

2010 SXA B1	2010	China: Xi'an, Shanxi	sputu m	2	19 62	plas mid	1	64	64	64	32	256	0.5	16	2	0.5	>256	32	8	16
2010 ZJA B1	2010	China: Hangzhou, Zhejiang	blood	2	21 8	chro moso me	1	32	16	64	32	256	1	32	4	0.5	4	32	16	16
2012 BJAB 1	2012	China: Beijing	blood	2	19 62	chro moso me	2	>32	16	64	32	>256	1	32	4	1	>256	>64	32	64
2012 GDA B1	2012	China: Guangzhou, Guangdong	bronch ial	2	20 8	chro moso me	1	>32	32	64	32	>256	0.5	32	8	1	>256	64	32	64
2014 LNA B2	2014	China: Shenyang, Liaoning	blood	2	36 8	chro moso me	2	>32	32	4	64	>256	0.5	16	1	0.5	>256	16	4	16
2018 BJAB 4	2018	China: Beijing	trache al aspirat e	2	19 68	chro moso me	1	32	16	>128	>256	>256	2	32	4	2	>256	>64	32	32

MIC, minimum inhibitory concentration; TZP, piperacillin/tazobactam; SXT, trimethoprim/sulfamethoxazo.